CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback